Related Experiment Videos
Structural consequences of tumor-derived mutations in p16INK4a probed by limited proteolysis
1Department of Biochemistry, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, Connecticut 06032, USA.
Abstract:
The cyclin-dependent kinase inhibitor p16(INK4a) (hereafter p16) functions as a multiple tumor suppressor. Mutations in p16, which are distributed throughout the entire protein, have been identified in a variety of human cancers and cancer-derived cell lines. It is unclear how tumor-derived mutations disrupt the structure and function of p16, especially since many of these mutations are located far away from the cyclin-dependent kinase binding site. In this study, we investigated the effect of two tumor-derived mutations, P81L and V126D, on the structure of p16 by limited proteolysis. The proteolytic products were characterized by gel electrophoresis, HPLC, and mass spectrometry. Our results show that the N-terminal half of p16 is significantly more sensitive to proteolysis in both tumor-derived mutant proteins than in the wild type, suggesting that this region is particularly unstable. Interestingly, the N-terminal half of p16 contains many residues that are important for cyclin-dependent kinase binding. Thus, our results provide a structural mechanism by which tumor-derived mutations inactivate the function of p16 and suggest that stabilization of the N-terminal region could be a useful strategy for future therapeutic development.
Insights
Tumor mutations destabilize the p16 protein
Area of Science:
- Molecular Biology
- Cancer Research
- Structural Biology
Background:
- The cyclin-dependent kinase inhibitor p16 (p16INK4a) is a crucial tumor suppressor.
- Mutations in p16 are common in various human cancers.
- The structural impact of these mutations, especially those distant from the active site, remains unclear.
Purpose of the Study:
- To investigate the structural consequences of tumor-derived mutations in p16.
- To understand how mutations affect p16 protein stability and function.
Main Methods:
- Limited proteolysis was used to assess p16 protein structure.
- Proteolytic products were analyzed using gel electrophoresis, HPLC, and mass spectrometry.
- The effects of specific mutations (P81L and V126D) were compared to wild-type p16.
Main Results:
- Tumor-derived mutations (P81L, V126D) significantly increased the susceptibility of the N-terminal region of p16 to proteolysis.
- This indicates enhanced instability in the N-terminal half of mutant p16 proteins.
- The N-terminal region is critical for binding to cyclin-dependent kinases.
Conclusions:
- Tumor-derived mutations can destabilize the p16 protein structure, particularly its N-terminal region.
- This structural instability provides a mechanism for p16 inactivation in cancer.
- Stabilizing the N-terminal region of p16 may offer a therapeutic strategy.